The development came after AstraZeneca Pharma India approached the drug regulator after an analysis “indicated a potential detrimental effect on overall survival for Olaparib compared to the chemotherapy control arm in the subgroup of patients who had received three or more prior lines of chemotherapy”, said a letter by the Central Drugs Standard Control Organisation to state drug regulators dated May 16., The development came after AstraZeneca Pharma India approached the drug regulator after an analysis “indicated a potential detrimental effect on overall survival for Olaparib compared to the chemotherapy control arm in the subgroup of patients who had received three or more prior lines of chemotherapy”, said a letter by the Central Drugs Standard Control Organisation to state drug regulators dated May 16., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way